Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.

@article{Teoh2011DasatinibH,
  title={Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.},
  author={Deanna G.K. Teoh and Tina A. Ayeni and Jennifer M. Rubatt and David J Adams and Lisa A. Grace and Mark D. Starr and William T. Barry and Andrew Berchuck and Susan K. Murphy and Angeles Alvarez Secord},
  journal={Gynecologic oncology},
  year={2011},
  volume={121 1},
  pages={
          187-92
        }
}
PURPOSE To explore the activity of dasatinib alone and in combination with paclitaxel and carboplatin in ovarian cancer cells and to determine if dasatinib activity can be predicted based on evaluation of the SRC pathway. EXPERIMENTAL DESIGN Microarray analysis was performed for IGROV1, OVCAR3, A2780 and SKOV3 ovarian cancer cells and the status of the genomic SRC signature pathway was determined. Cells were treated with carboplatin, paclitaxel and dasatinib individually and in combination… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

Similar Papers

Loading similar papers…